Comparison
Semaglutide vs Tirzepatide
One hormone pathway versus two
The key difference
Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GLP-1 and GIP receptors in a single molecule.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Evidence | FDA-approved drug | FDA-approved drug |
| Status | Prescription drug. FDA-approved for specific indications. | Prescription drug. FDA-approved for specific indications. |
| Also known as | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Researched for | Weight & metabolism | Weight & metabolism |
| Evidence strength | FDA-approved drug | FDA-approved drug |
What else differs
- Both are FDA-approved prescription medicines with large human trial programs behind them.
- In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks.
- Both are once-weekly injections, and both most commonly cause gastrointestinal side effects.
- Their approved uses overlap (type 2 diabetes, chronic weight management) but are not identical.
Bottom line
These are the two best-studied compounds in the space. Which one fits a person is a prescriber decision based on health history, response, and access.
Read the research
Semaglutide on PubMed →
Tirzepatide on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.